Nuveen
BBIO icon

Nuveen’s BridgeBio Pharma BBIO Stock Holding History

Nuveen’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$42.7M Buy
572,789
+10,093
+2% +$707K 0.01% 803
2026
Q1 		$41.8M Buy
562,696
+67,911
+14% +$4.92M 0.01% 732
2025
Q4 		$37.8M Sell
494,785
-9,325
-2% -$612K 0.01% 785
2025
Q3 		$26.2M Buy
504,110
+92,203
+22% +$4.5M 0.01% 976
2025
Q2 		$17.8M Sell
411,907
-21,205
-5% -$771K ﹤0.01% 1177
2025
Q1 		$15M Buy
433,112
+30,186
+7% +$1.02M ﹤0.01% 1309
2024
Q4 		$11.1M Sell
402,926
-43,010
-10% -$1.11M ﹤0.01% 1543
2024
Q3 		$11.4M Sell
445,936
-121,745
-21% -$3.2M ﹤0.01% 1530
2024
Q2 		$14.4M Buy
567,681
+256,322
+82% +$7.01M ﹤0.01% 1347
2024
Q1 		$9.63M Sell
311,359
-6,288
-2% -$214K ﹤0.01% 1610
2023
Q4 		$12.8M Sell
317,647
-230,567
-42% -$6.92M ﹤0.01% 1429
2023
Q3 		$14.5M Sell
548,214
-360,457
-40% -$10.2M 0.01% 1253
2023
Q2 		$15.6M Buy
908,671
+387,594
+74% +$5.83M 0.01% 1241
2023
Q1 		$8.64M Buy
521,077
+170,368
+49% +$1.99M ﹤0.01% 1572
2022
Q4 		$2.67M Sell
350,709
-18,855
-5% -$181K ﹤0.01% 2250
2022
Q3 		$3.67M Sell
369,564
-291,267
-44% -$3.03M ﹤0.01% 2075
2022
Q2 		$6M Buy
660,831
+252
+0% +$2.11K ﹤0.01% 1825
2022
Q1 		$6.9M Buy
660,579
+288,873
+78% +$2.96M ﹤0.01% 1878
2021
Q4 		$6.2M Sell
371,706
-193,668
-34% -$8.19M ﹤0.01% 1990
2021
Q3 		$26.5M Sell
565,374
-29,814
-5% -$1.6M 0.01% 1077
2021
Q2 		$36.3M Buy
595,188
+157,750
+36% +$9.01M 0.01% 934
2021
Q1 		$26.9M Buy
437,438
+114,963
+36% +$7.52M 0.01% 1100
2020
Q4 		$22.9M Sell
322,475
-166
-0.1% -$8.01K 0.01% 1172
2020
Q3 		$12.1M Sell
322,641
-10,578
-3% -$333K ﹤0.01% 1391
2020
Q2 		$10.9M Sell
333,219
-55,429
-14% -$1.69M ﹤0.01% 1429
2020
Q1 		$11.3M Sell
388,648
-147,515
-28% -$4.57M 0.01% 1219
2019
Q4 		$18.8M Buy
536,163
+448,791
+514% +$12.4M 0.01% 1209
2019
Q3 		$1.88M Buy
+87,372
New +$2.42M ﹤0.01% 2434

Other funds holding BBIO

JT
Jupiter Topco New York $245B AUM
KKRC
Kohlberg Kravis Roberts & Co New York $5.71B AUM 72.37% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
ACM
Aisling Capital Management New York $472M AUM 106.83% 1-Year Est. Return

Nuveen's BBIO Position: Q2 2026 in Review

Nuveen increased its BridgeBio Pharma (BBIO) stake by 1.8% in Q2 2026, buying an estimated $707K and bringing the position to 572,789 shares worth $42.7M. The position accounts for 0.01% of the portfolio, ranked #803.

Nuveen first reported a position in BBIO in Q3 2019 and has held it in 28 quarters since. 474 funds tracked by Wall St. Rank hold BBIO as of Q2 2026.

  • Nuveen held 572,789 shares of BridgeBio Pharma worth $42.7M as of Q2 2026.
  • Nuveen bought 10,093 BridgeBio Pharma shares in Q2 2026, an estimated $707K.
  • BridgeBio Pharma made up 0.01% of Nuveen's portfolio in Q2 2026, its #803 holding.
  • Nuveen first reported a position in BridgeBio Pharma in Q3 2019 and has held it in 28 quarters since.
  • 474 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2026.

Based on Nuveen's 13F filing for Q2 2026, filed 11 Aug 2026.